AI and automation – often referred to as hyperautomation – are evolving rapidly with industry experts emphasizing their increasing ability to operate independently and make intelligent decisions.
By combining powerful generative AI with business expertise, organizations can accelerate and streamline their processes like never before.
I recently sat down with Mayank Anand, Vice President of Global Clinical Operations at a leading pharmaceutical company, to discuss the critical role AI and automation play in driving innovation while maintaining quality and trust in drug development.
The pharmaceutical industry is leveraging cutting-edge technology to speed up the delivery of new treatments without compromising transparency or trust. Our discussion explored key use cases including data cleansing, synthetic data, digital twins and pharmacoeconomics – demonstrating how AI and automation are enabling faster high-quality outcomes.
However, these advancements don’t replace the need for skilled professionals. Instead, they emphasize the importance of equipping individuals with the expertise to apply and scale AI and automation effectively.
To dive deeper into the transformative impact of AI in life sciences, watch my full conversation with Mayank here:
SUBSCRIBE TO THE SAS INSIGHTS NEWSLETTER
#Trust #process #Hyperautomation #drug #development #accelerates #timetomarket
